Futura Medical Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB0033278473
GBP
0.01
-0.09 (-89.38%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 2.89%

  • The company has been able to generate a Return on Equity (avg) of 2.89% signifying low profitability per unit of shareholders funds
  • NO KEY NEGATIVE TRIGGERS
2

Risky -

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 3 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.21

stock-summary
Return on Equity

-206.60%

stock-summary
Price to Book

1.06

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-92.15%
0%
-92.15%
6 Months
-96.97%
0%
-96.97%
1 Year
-97.25%
0%
-97.25%
2 Years
-97.62%
0%
-97.62%
3 Years
-96.81%
0%
-96.81%
4 Years
-97.77%
0%
-97.77%
5 Years
-94.63%
0%
-94.63%

Futura Medical Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
54.84%
EBIT Growth (5y)
2.23%
EBIT to Interest (avg)
-5.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
1.20
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
9.43%
ROE (avg)
2.89%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.69
EV to EBIT
-1.18
EV to EBITDA
-1.20
EV to Capital Employed
-7.55
EV to Sales
0.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-206.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Futura Medical Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -12.07% vs -16.00% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.00",
          "val2": "-6.70",
          "chgp": "-4.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.50",
          "val2": "-5.80",
          "chgp": "-12.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,245.70%",
          "val2": "0.00%",
          "chgp": "-224.57%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
3.10
0.00
Operating Profit (PBDIT) excl Other Income
-7.00
-6.70
-4.48%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.50
-5.80
-12.07%
Operating Profit Margin (Excl OI)
-2,245.70%
0.00%
-224.57%
USD in Million.
Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -12.07% vs -16.00% in Dec 2022

stock-summaryCompany CV
About Futura Medical Plc stock-summary
stock-summary
Futura Medical Plc
Pharmaceuticals & Biotechnology
Futura Medical plc is a United Kingdom-based pharmaceutical company that develops products for consumer healthcare. The Company is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. It is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin. It specializes in sexual health and pain relief, and has approximately five products in its development pipeline, which include CSD500, MED2002, TPR100, TIB200 and SPR300. Its CSD500 product incorporates an erectogenic gel (known as Zanifil gel) to help men maintain a firmer erection during intercourse whilst wearing a condom. Its MED2002 is a gel applied directly to the penis for the treatment of male erectile dysfunction (ED). The Company's TPR100 is a gel to provide pain relief. Its SPR300 is a gel, which combines methyl salicylate and menthol with the DermaSys delivery system.
Company Coordinates stock-summary
Company Details
Unit 40, Surrey Technology Centre, Occam Road GUILDFORD None : GU2 7YG
stock-summary
Tel: 44 1483 68567044 014 83685670
stock-summary
Registrar Details